April 8, 2015
Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that Dr. Mitchell Tyler, Director of Research & Development, will be presenting a poster at the 2015 Annual Conference on Vaccine Research in Bethesda, MD April 13-15, 2015. Dr. Tyler is also a finalist for the 2015 Maurice R. Hilleman Early-Stage Career Investigator Award.
Dr. Federica Pericle, President & CEO, will be attending the 7th Annual ChinaBio Partnering Forum in Shanghai, China, April 15-16, 2015. Dr. Pericle will be available for one-on-one meetings, and welcomes the opportunity to discuss Agilvax’s novel vaccine / immunotherapy discovery and development platform.
Agilvax develops vaccines targeting infectious diseases and immunotherapies to combat cancer utilizing its proprietary virus-like particle (VLP) platform technology. The company has a pipeline and platform that is based on VLPs derived from RNA bacteriophage that have been engineered to incorporate novel peptide epitopes. The platform allows the company to rapidly identify ideal VLP candidates, moving from hypothesis to preclinical proof of concept in months. The Company was founded in 2011 and has headquarters in Albuquerque, NM, USA.
Federica Pericle, PhD, MBA
President and Chief Executive Officer